Abbott Receives European CE Mark Approval for FreeStyle Navigator(R) Continuous Glucose Monitoring System

    ABBOTT PARK, Ill., June 6 /PRNewswire-FirstCall/ -- Abbott (NYSE:   ABT)
 announced today that it received European CE Mark (Conformite Europeene)
 approval for the FreeStyle Navigator(R) Continuous Glucose Monitoring
 System for people with diabetes.
     The World Health Organization (WHO) estimates that 180 million people
 worldwide have diabetes, and this number is likely to double by 2030.
 Diabetes is a chronic disease that occurs when the pancreas does not
 produce enough insulin, or when the body cannot effectively use the insulin
 it produces. For millions of people with diabetes, checking their blood
 glucose on a regular basis is a fact of life. Most people with diabetes who
 use insulin check their glucose level a minimum of four times per day,
 often more frequently.
     The FreeStyle Navigator System is designed to discreetly measure
 glucose levels once per minute without the recurring pain and hassle that
 can accompany conventional blood glucose testing. With early warning alarms
 that alert the patient to potential highs and lows, and by providing
 glucose information once per minute (equivalent to 1440 times per day), the
 FreeStyle Navigator system provides a more complete picture of where the
 person's glucose level is, and where it is going -- up or down. For people
 with diabetes, less time spent in either a hypoglycemic (low blood sugar)
 or hyperglycemic (high blood sugar) state has been correlated with better
 diabetes management and reduced risk for a number of serious short- and
 long-term diabetes-related complications(1).
     Abbott's FreeStyle Navigator System offers a number of key advances for
 people with diabetes. The system monitors glucose levels by measuring and
 transmitting glucose information once per minute to the pager-sized
 receiver, which can be clipped to a belt or carried in a pocket or purse.
 It also provides alarms before glucose levels become too high or too low,
 displays five directional trend arrows to help people understand if glucose
 is rising or falling, and stores historical data and glucose trend
 information. The FreeStyle Navigator System features a disposable sensor
 that is worn for up to five days, then replaced; a transmitter with a 10
 foot (3 meter) range; and a wireless receiver with a built-in FreeStyle(R)
 blood glucose meter.
     "Early feedback about Abbott's new continuous glucose monitoring system
 is very promising," said Thomas Danne, M.D., Ph.D, professor at Bult
 Diabetes Center in Hanover, Germany. "This new system for people with
 diabetes has significant potential to meet the critical needs of diabetes
 patients by giving them early warnings for highs and lows along with
 frequent information about their glucose levels," Danne added.
     "The FreeStyle Navigator System provides people with diabetes with a
 tremendous amount of new information that is designed to help them act in
 advance rather than react -- this represents an important new advance in
 diabetes management," said Chip Hance, senior vice president, Diabetes Care
 Operations, Abbott. "This technology exemplifies Abbott's innovative
 approach to glucose testing and our commitment to making diabetes-related
 technology easier to use."
     The FreeStyle Navigator Continuous Glucose Monitoring System is
 indicated for adults with diabetes, age 18 and older. The system may be
 used to continually measure glucose levels, however, to confirm
 hypoglycemia or pending hypoglycemia, or prior to injecting insulin, a
 confirming blood glucose test (fingerstick measurement) should be done.
     Clinical Trial Results
     The accuracy, safety and efficacy of the FreeStyle Navigator System
 have been demonstrated in two separate pivotal clinical trials, including a
 five-day in-clinic study and a study of people with type 1 and type 2
 diabetes at home.
     Five-Day In-Clinic Study(2): Abbott conducted a study to test the
 accuracy of its FreeStyle Navigator System in 58 subjects ranging in age
 from 18 to 64. This study met its primary endpoint of demonstrated accuracy
 and stability over five days of wear. Using the Clarke Error Grid (CEG),
 comparing readings from a lab reference to a reading from the FreeStyle
 Navigator Continuous Glucose Monitoring System at a specific point in time,
 98.3 percent of measurements were in the most accurate zones (zones A and
 B).
     Home Use Study(3): In a study on the safety and efficacy of the
 FreeStyle Navigator System, 123 people with type 1 and type 2 diabetes used
 the product in their homes for a total of 40 days, wearing the sensor on
 the back of their upper arm or abdomen. Continuous glucose values were not
 visible to the user (masked phase) during the first half of the study, then
 glucose values were visible during the second half of the study (unmasked
 phase). A Clarke Error Grid (CEG) analysis demonstrated that 96.8 percent
 of the values were in the most accurate zones. Patients in the study with
 type 1 diabetes spent significantly less time in a hypoglycemic state
 during the unmasked phase of the trial.
     About the FreeStyle Navigator System
     The FreeStyle Navigator System is composed of three parts: a sensor, a
 transmitter and a receiver. The sensor, worn for five days and then
 replaced, is placed just under the skin and is attached to plastic sensor
 mount with adhesive to adhere to the skin, like a patch. The transmitter
 snaps into the sensor mount and sends glucose information wirelessly to the
 pager-sized receiver. The system discreetly measures glucose levels once
 per minute; provides high / low glucose alarms based on customizable,
 physician- and patient-determined levels; and delivers early-warning alarms
 that indicate if glucose levels are likely to be too high or too low 10, 20
 or 30 minutes in advance. The system also stores up to 60 days worth of
 glucose information that can be analyzed by the user or a healthcare
 professional.
     About Diabetes
     The World Health Organization (WHO) estimates that 180 million people
 worldwide have diabetes, a chronic disease that occurs when the pancreas
 does not produce enough insulin, or, when the body cannot effectively use
 the insulin it produces. Insulin is a hormone that regulates blood sugar.
 Hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) is a
 common effect of uncontrolled diabetes and over time can lead to serious
 complications and cause damage to the body's systems, including the heart,
 blood vessels, eyes, kidneys, and nerves.(4)
     About Abbott Diabetes Care
     Abbott Diabetes Care is a leader in developing, manufacturing and
 marketing glucose monitoring systems designed to help patients better
 manage their diabetes. Abbott Diabetes Care is committed to developing
 products that reduce the discomfort and inconvenience of blood glucose
 monitoring and to introducing innovative systems that are easier to use,
 require smaller blood samples and provide faster results. Abbott Diabetes
 Care markets several leading-edge glucose monitoring systems and test
 strips worldwide for use in both home and hospital settings. Additional
 information about Abbott Diabetes Care may be found at
 http://www.abbottdiabetescare.com and http://www.abbottdiabetescare.co.uk.
     About Abbott
     Abbott is a global, broad-based health care company devoted to the
 discovery, development, manufacture and marketing of pharmaceuticals and
 medical products, including nutritionals, devices and diagnostics. The
 company employs 65,000 people and markets its products in more than 130
 countries.
     Abbott's news releases and other information are available on the
 company's Web site at http://www.abbott.com.
     (1) Data available from the American Diabetes Association Web site:
 http://diabetes.org/diabetes-research/research-home.jsp.
     (2) Study results published in the May 2007 issue of the Journal of
 Diabetes Care.
     (3) Data results presented in a poster (number 2-LB) entitled,
 "Performance of the FreeStyle Navigator Continuous Glucose Monitoring
 System During Home Use" at the 66th annual Scientific Sessions of the
 American Diabetes Association.
     (4) World Health Organization (WHO) Web site:
 http://www.who.int/mediacentre/factsheets/fs312/en/index.html
 
 

SOURCE Abbott

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.